While a federal judge has paused the funding cuts, the uncertainty has researchers concerned about the future of scientific ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

(Reuters) - Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American ...

Not every personal loan has funding available the same or next business day for quick cash, but some lenders offer this option. The best personal loans for quick access offer an easy application ...

According to the Organization for Economic Co-Operation and Development (OECD), women-only founders accounted for 2% of venture capital funding in 2020. Small business grants are another option ...

If successful, the trial will position Ab&B to enter a market that is already served by Merck’s 23-valent vaccine Pneumovax and Pfizer’s ... The biotech is seeking funding for the programs ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been underperforming for ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...